Information Provided By:
Fly News Breaks for May 22, 2018
ONCE, BMRN
May 22, 2018 | 09:52 EDT
Citi analyst Robyn Karnauskas said BioMarin (BMRN) shares should not be trading lower after the company's report of an update to its previously reported results of a Phase 1/2 study of its investigational gene therapy treatment for severe hemophilia A, stating that the durability "looks good" and that patient interest in high dose/higher factor level supports the idea that the company's approach may be better than competitor Spark Therapeutics (ONCE). Karnauskas has a Buy rating on BioMarin shares, which are down about $84.63 in morning trading.
News For BMRN;ONCE From the Last 2 Days
There are no results for your query BMRN;ONCE